Vitrolife Stock Price, News & Analysis

Vitrolife held its Annual General Meeting, approving several key decisions for 2025. Shareholders approved a dividend of SEK 1.10 per share for 2024, with May 2, 2025, set as the record date.

The board saw the re-election of five members, with Jón Sigurdsson appointed as Chairman. Total board remuneration increased to SEK 3.67 million, up from SEK 3.3 million. Deloitte AB was re-elected as auditor.

Key authorizations granted include:

• Permission to issue up to 13,544,719 shares (10% of share capital)
• Authority to acquire company shares (max 10% of total shares)
• Implementation of a share-based incentive program with 480,000 warrants

The meeting also approved new guidelines for executive management compensation.

Vitrolife AB held its Annual General Meeting on April 29, 2025, announcing key decisions including a dividend of SEK 1.10 per share for 2024. The board saw the re-election of members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson, and Karen Lykke Sørensen, with Jón Sigurdsson elected as Chairman.

Board remuneration was increased to SEK 3.67 million, with the Chairman receiving SEK 1.35 million. The company authorized potential issuance of up to 13,544,719 shares (10% of share capital) and approved share buyback authorization. Deloitte AB was re-elected as auditor.

The meeting also approved new executive management compensation guidelines and resolved to enter a share swap agreement for LTIP 2025 implementation.

Vitrolife reported Q1 2025 financial results showing mixed regional performance. Sales reached SEK 842 million, representing a 1% increase in local currencies and flat growth in SEK. Excluding discontinued business, growth was 3%. Regional performance varied significantly with EMEA showing strong growth of 8% (14% excluding discontinued business), Americas growing 9%, while APAC declined 15%.

By product category, excluding discontinued business, Consumables grew 6%, while Technologies declined 5% and Genetics increased 4%. The company's gross margin improved slightly to 57.4% from 57.1%. EBITDA decreased to SEK 257 million with a margin of 30.6%, impacted by a negative foreign exchange effect of SEK 13 million. Operating cash flow was SEK 69 million, and net income reached SEK 100 million, resulting in earnings per share of SEK 0.74.

Vitrolife Group (VTRLY) has announced the appointment of Pär Ihrskog as their new Chief Financial Officer, effective October 10, 2025. Ihrskog, currently serving as CFO at Bufab Group, brings significant financial expertise from his previous roles, including his position as Group CFO/CIO at Embellence Group and various finance roles at SKF, where he gained international experience in the U.S. and China.

The new CFO holds a master's degree in business administration and will succeed Helena Wennerström, who will continue as acting CFO until Ihrskog assumes the position. CEO Bronwyn Brophy O'Connor expressed confidence that Ihrskog's extensive financial expertise and leadership experience in listed companies will support Vitrolife's strategy for sustainable profitable growth.

Vitrolife AB (VTRLY) has announced a conference call to present its Q1 2025 interim report scheduled for Thursday, April 24, 2025, at 10:00 AM CET. The presentation will be conducted in English.

Key participants from Vitrolife include CEO Bronwyn Brophy O'Connor and acting CFO Helena Wennerström. The interim report press release will be published at 8:00 AM CET on the same day, with presentation materials available on the company website before the call.

Interested parties must register to receive telephone numbers and access PINs for the conference. A recorded version will be accessible for seven days following the call at +44 (0) 20 3451 9993 using access code 8141544#.

Vitrolife Group (VTRLY) has announced strategic changes to its executive management team, with a heightened focus on innovation. Rickard Ericsson, who previously served as SVP Consumables and SVP Sales & Marketing, has been appointed as SVP Innovation with immediate effect. In his new role, Ericsson will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access.

The new Executive Management Team includes CEO Bronwyn Brophy O'Connor, Acting CFO Helena Wennerström, COO Ermanno Sironi, SVP Innovation Rickard Ericsson, SVP Sales & Marketing Olivia Natens, and CHRO Jessica Jonasson. The company maintains its financial reporting structure across three regions: EMEA, Americas, and APAC, with business areas reported as product groups: Consumables, Technologies, and Genetics.

Vitrolife Group has released its Annual and Sustainability Report for 2024 on March 27, 2025. The report is now accessible digitally in both English and Swedish on the company's website, with the European Single Electronic Format (ESEF) version available in Swedish.

The company has adopted a digital-first approach, choosing not to automatically print or distribute hard copies. However, stakeholders who need physical copies can request them by contacting Vitrolife Group via email at investors@vitrolife.com or by phone at +46 (0) 31 721 80 00.

The disclosure was made public in compliance with the Swedish Securities Markets Act (2007:528), with Amelie Wilson serving as the Investor Relations contact.

Vitrolife AB (VTRLY) has announced its Annual General Meeting scheduled for April 29, 2025 at Elite Park Avenue Hotel in Gothenburg, Sweden. Key proposals include a dividend of SEK 1.10 per share with a record date of May 2, 2025.

The Election Committee proposes maintaining a five-member board, with Jón Sigurdsson continuing as Chairman. Total board remuneration is proposed to increase by 11.2% to SEK 3,670,000, with the Chairman's compensation set at SEK 1,350,000.

Shareholders must be recorded in Euroclear Sweden AB's register by April 17, 2025, and notify their attendance by April 23, 2025. The meeting will also address the re-election of Deloitte AB as auditor and authorizations for new share issuance and company share buybacks.

Vitrolife Group has acknowledged a PGT-A class action lawsuit filed against Vitrolife AB, Vitrolife Inc, and Igenomix USA in the Southern District of Florida court. The company has not yet been formally served with the complaint. The announcement notes that similar class actions were initiated against other industry peers providing PGT-A testing services during Q4 2024.

The company states it will evaluate the class action and its potential scope with US legal counsel and will provide market updates when additional information becomes available.